Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'COMT INHIBITOR' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 58 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Myllyla, VV; Kultalahti, ER; Haapaniemi, H; Leinonen, M
      Twelve-month safety of entacapone in patients with Parkinson's disease

      EUROPEAN JOURNAL OF NEUROLOGY
    2. Bonifacio, MJ; Vieira-Coelho, MA; Soares-da-Silva, P
      Expression and characterization of rat soluble catechol-O-methyltransferase fusion protein

      PROTEIN EXPRESSION AND PURIFICATION
    3. Shan, DE; Lee, SJ; Chao, LY; Yeh, SI
      Gait analysis in advanced Parkinson's disease - effect of levodopa and tolcapone

      CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
    4. Haasio, K; Sopanen, L; Vaalavirta, L; Linden, IB; Heinonen, EH
      Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat

      JOURNAL OF NEURAL TRANSMISSION
    5. Najib, J
      Entacapone: A catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease

      CLINICAL THERAPEUTICS
    6. Leppanen, J; Wegelius, E; Nevalainen, T; Jarvinen, T; Gynther, J; Huuskonen, J
      Structural studies of acyl esters of entacapone

      JOURNAL OF MOLECULAR STRUCTURE
    7. Lyytinen, J; Kaakkola, S; Gordin, A; Kultalahti, ER; Teravainen, H
      Entacapone and selegiline with L-dopa in patients with Parkinson's disease: an interaction study

      PARKINSONISM & RELATED DISORDERS
    8. Meco, G; Vanacore, N; Locuratolo, N; Bonifati, V; Vella, C; Giovani, A; Tubani, L; Baratta, L; Mastrocola, C
      Heart rate variability in Parkinson's disease patients treated with tolcapone

      PARKINSONISM & RELATED DISORDERS
    9. Chong, BS; Mersfelder, TL
      Entacapone

      ANNALS OF PHARMACOTHERAPY
    10. Ogawa, N
      Factors affecting levodopa effects in Parkinson's disease

      ACTA MEDICA OKAYAMA
    11. Inzelberg, R; Carasso, RL; Schechtman, E; Nisipeanu, P
      A comparison of dopamine agonists and catechol-O-methyltransferase inhibitors in Parkinson's disease

      CLINICAL NEUROPHARMACOLOGY
    12. Jorga, K; Fotteler, B; Banken, L; Snell, P; Steimer, JL
      Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    13. LeWitt, PA
      New drugs for the treatment of Parkinson's disease

      PHARMACOTHERAPY
    14. Savolainen, J; Forsberg, M; Taipale, H; Mannisto, PT; Jarvinen, K; Gynther, J; Jarho, P; Jarvinen, T
      Effects of aqueous solubility and dissolution characteristics on oral bioavailability of entacapone

      DRUG DEVELOPMENT RESEARCH
    15. Savolainen, J; Leppanen, J; Forsberg, M; Taipale, H; Nevalainen, T; Huuskonen, J; Gynther, J; Mannisto, PT; Jarvinen, T
      Synthesis and in vitro/in vivo evaluation of novel oral N-alkyl- and N,N-dialkyl-carbamate esters of entacapone

      LIFE SCIENCES
    16. Liu, H; Iacono, RP; Schoonenberg, T; Kuniyoshi, S; Buchholz, J
      A comparative study on neurochemistry of cerebrospinal fluid in advanced Parkinson's disease

      NEUROBIOLOGY OF DISEASE
    17. Schwid, SR; Kieburtz, K; Nutt, J; McDermott, M; Kayson, E; Chase, T; Fahn, S; Greenamyre, T; Lang, A; Penney, J; Shoulson, I
      The impact of remacemide hydrochloride on levodopa concentrations in Parkinson's disease

      CLINICAL NEUROPHARMACOLOGY
    18. Napolitano, A; Del Dotto, P; Petrozzi, L; Dell'Agnello, G; Bellini, G; Gambaccini, G; Bonuccelli, U
      Pharmacokinetics and pharmacodynamics of L-DOPA after acute and 6-week tolcapone administration in patients with Parkinson's disease

      CLINICAL NEUROPHARMACOLOGY
    19. Luer, MS
      Interventions to achieve tonic exposure to levodopa: Delaying or preventing the onset of motor complications

      PHARMACOTHERAPY
    20. Guay, DRP
      Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease

      PHARMACOTHERAPY
    21. Fava, M; Rosenbaum, JF; Kolsky, AR; Alpert, JE; Nierenberg, AA; Spillmann, M; Moore, C; Renshaw, P; Bottiglieri, T; Moroz, G; Magni, G
      Open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    22. Rouru, J; Gordin, A; Huupponen, R; Huhtala, S; Savontaus, E; Korpela, K; Reinikainen, K; Scheinin, M
      Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    23. SAMII A; LETWIN SR; CALNE DB
      PROSPECTS FOR NEW DRUG-TREATMENT IN IDIOPATHIC PARKINSONISM

      Drug discovery today
    24. GEROK F; DEUSCHL G
      CATECHOL-O-METHYLTRANSFERASE INHIBITION IN THE TREATMENT OF PARKINSONS-DISEASE

      Aktuelle Neurologie
    25. DESANTI C; GIULIANOTTI PC; PIETRABISSA A; MOSCA F; PACIFICI GM
      CATECHOL-O-METHYLTRANSFERASE - VARIATION IN ENZYME-ACTIVITY AND INHIBITION BY ENTACAPONE AND TOLCAPONE

      European Journal of Clinical Pharmacology
    26. RINNE UK; LARSEN JP; SIDEN A; WORMPETERSEN J
      ENTACAPONE ENHANCES THE RESPONSE TO LEVODOPA IN PARKINSONIAN-PATIENTSWITH MOTOR FLUCTUATIONS

      Neurology
    27. PAHWA R; KOLLER WC
      ADVANCES IN THE TREATMENT OF PARKINSONS-DISEASE

      Medicamentos de actualidad
    28. ADLER CH; SINGER C; OBRIEN C; HAUSER RA; LEW MF; MAREK KL; DORFLINGER E; PEDDER S; DEPTULA D; YOO K
      RANDOMIZED, PLACEBO-CONTROLLED STUDY OF TOLCAPONE IN PATIENTS WITH FLUCTUATING PARKINSON-DISEASE TREATED WITH LEVODOPA-CARBIDOPA

      Archives of neurology
    29. MYLLYLA VV; JACKSON M; LARSEN JP; BAAS H
      EFFICACY AND SAFETY OF TOLCAPONE IN LEVODOPA-TREATED PARKINSONS-DISEASE PATIENTS WITH WEARING-OFF PHENOMENON - A MULTICENTER, DOUBLE-BLIND,RANDOMIZED, PLACEBO-CONTROLLED TRIAL

      European journal of neurology
    30. MCNEELY W; DAVIS R
      ENTACAPONE

      CNS DRUGS
    31. LEWITT PA
      NEW OPTIONS FOR TREATMENT OF PARKINSONS-DISEASE

      Bailliere's clinical neurology
    32. SMITH LA; GORDIN A; JENNER P; MARSDEN CD
      ENTACAPONE ENHANCES LEVODOPA-INDUCED REVERSAL OF MOTOR DISABILITY IN MPTP-TREATED COMMON MARMOSETS

      Movement disorders
    33. ALLAIN H; BENTUEFERRER D
      INTERROGATIONS AND SOLUTIONS CONCERNING PARKINSONS-DISEASE

      La Presse medicale
    34. KUHN W; MULLER T
      THERAPY OF PARKINSONS-DISEASE .2. NEW THERAPEUTIC CONCEPTS FOR TREATING LOCOMOTOR SYMPTOMS

      Fortschritte der Neurologie, Psychiatrie
    35. DING YS; SUGANO Y; KOOMEN J; AGGARWAL D
      SYNTHESIS OF [F-18] RO41-0960, A POTENT CATECHOL-O-METHYLTRANSFERASE INHIBITOR, FOR PET STUDIES

      Journal of labelled compounds & radiopharmaceuticals
    36. HEERINGA MJ; DAGOSTINI F; DEBOER P; DAPRADA M; DAMSMA G
      EFFECT OF MONOAMINE-OXIDASE-A AND MONOAMINE-OXIDASE-B AND OF CATECHOL-O-METHYLTRANSFERASE INHIBITION ON L-DOPA-INDNCED CIRCLING BEHAVIOR

      Journal of neural transmission
    37. DOUDET DJ; CHAN GLY; HOLDEN JE; MORRISON KS; WYATT RJ; RUTH TJ
      EFFECTS OF CATECHOL-O-METHYLTRANSFERASE INHIBITION ON THE RATES OF UPTAKE AND REVERSIBILITY OF 6-FLUORO-L-DOPA TRAPPING IN MPTP-INDUCED PARKINSONISM IN MONKEYS

      Neuropharmacology
    38. RAJPUT AH; MARTIN W; SAINTHILAIRE MH; DORFLINGER E; PEDDER S
      TOLCAPONE IMPROVES MOTOR FUNCTION IN PARKINSONIAN-PATIENTS WITH THE WEARING-OFF PHENOMENON - A DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL

      Neurology
    39. BORGES N; VIEIRACOELHO MA; PARADA A; SOARESDASILVA P
      STUDIES ON THE TIGHT-BINDING NATURE OF TOLCAPONE INHIBITION OF SOLUBLE AND MEMBRANE-BOUND RAT-BRAIN CATECHOL-O-METHYLTRANSFERASE

      The Journal of pharmacology and experimental therapeutics
    40. ALBANESE A
      EMERGING TREATMENTS IN PARKINSONS-DISEASE

      European neurology
    41. NISSINEN E; KAHEINEN P; PENTTILA KE; KAIVOLA J; LINDEN IB
      ENTACAPONE, A NOVEL CATECHOL-O-METHYLTRANSFERASE INHIBITOR FOR PARKINSONS-DISEASE, DOES NOT IMPAIR MITOCHONDRIAL ENERGY-PRODUCTION

      European journal of pharmacology
    42. SPENCER CM; BENFIELD P
      TOLCAPONE

      CNS DRUGS
    43. RUOTTINEN HM; RINNE UK
      A DOUBLE-BLIND PHARMACOKINETIC AND CLINICAL DOSE-RESPONSE STUDY OF ENTACAPONE AS AN ADJUVANT TO LEVODOPA THERAPY IN ADVANCED PARKINSONS-DISEASE

      Clinical neuropharmacology
    44. RUOTTINEN HM; RINNE UK
      EFFECT OF ONE MONTHS TREATMENT WITH PERIPHERALLY ACTING CATECHOL-O-METHYLTRANSFERASE INHIBITOR, ENTACAPONE, ON PHARMACOKINETICS AND MOTOR RESPONSE TO LEVODOPA IN ADVANCED PARKINSONIAN-PATIENTS

      Clinical neuropharmacology
    45. ISHIKAWA T; DHAWAN V; CHALY T; ROBESON W; BELAKHLEF A; MANDEL F; DAHL R; MAROULEFF C; EIDELBERG D
      FLUORODOPA POSITRON EMISSION TOMOGRAPHY WITH AN INHIBITOR OF CATECHOL-O-METHYLTRANSFERASE - EFFECT OF THE PLASMA 3-O-METHYLDOPA FRACTION ONDATA-ANALYSIS

      Journal of cerebral blood flow and metabolism
    46. ILLI A; SUNDBERG S; OJALAKARLSSON P; SCHEININ M; GORDIN A
      SIMULTANEOUS INHIBITION OF CATECHOLAMINE-O-METHYLATION BY ENTACAPONE AND NEURONAL UPTAKE BY IMIPRAMINE - LACK OF INTERACTIONS

      European Journal of Clinical Pharmacology
    47. DAVIS TL; ROZNOSKI M; BURNS RS
      EFFECTS OF TOLCAPONE IN PARKINSONS PATIENTS TAKING L-DIHYDROXYPHENYLALANINE CARBIDOPA AND SELEGILINE/

      Movement disorders
    48. TOHGI H; ABE T; YAMAZAKI K; SAHEKI M; TAKAHASHI S; TSUKAMOTO Y
      EFFECTS OF THE CATECHOL-O-METHYLTRANSFERASE INHIBITOR TOLCAPONE IN PARKINSONS-DISEASE - CORRELATIONS BETWEEN CONCENTRATIONS OF DOPAMINERGICSUBSTANCES IN THE PLASMA AND CEREBROSPINAL-FLUID AND CLINICAL IMPROVEMENT

      Neuroscience letters
    49. NAPOLITANO A; CESURA AM; DAPRADA M
      THE ROLE OF MONOAMINE-OXIDASE AND CATECHOL O-METHYLTRANSFERASE IN DOPAMINERGIC NEUROTRANSMISSION

      Journal of neural transmission. Supplementum
    50. KLOCKGETHER T; LOSCHMANN PA; WULLNER U
      NEW DEVELOPMENTS IN NEUROLOGY

      Aktuelle Neurologie
    51. FREDRIKSSON A; ARCHER T
      SYNERGISTIC INTERACTIONS BETWEEN COMT- MAO-INHIBITORS AND L-DOPA IN MPTP-TREATED MICE/

      Journal of neural transmission
    52. KLOCKGETHER T; LOSCHMANN PA; WULLNER U
      NEW MEDICAL AND SURGICAL TREATMENTS FOR PARKINSONS-DISEASE

      Current opinion in neurology
    53. MOREAU JL; BORGULYA J; JENCK F; MARTIN JR
      TOLCAPONE - A POTENTIAL NEW ANTIDEPRESSANT DETECTED IN A NOVEL ANIMAL-MODEL OF DEPRESSION

      Behavioural pharmacology
    54. TOLOSA E; VALLDEORIOLA F
      MID-STAGE PARKINSONISM WITH MILD MOTOR FLUCTUATIONS

      Clinical neuropharmacology
    55. KAAKKOLA S; GORDIN A; MANNISTO PT
      GENERAL-PROPERTIES AND CLINICAL POSSIBILITIES OF NEW SELECTIVE INHIBITORS OF CATECHOL O-METHYLTRANSFERASE

      General pharmacology
    56. BRAUTIGAM K; SOHR R; MORGENSTERN R
      3-O-METHYL-DOPA IS NOT INVOLVED IN THE DEVELOPMENT OF BEHAVIORAL SUPERSENSITIVITY AFTER REPEATED L-DOPA ADMINISTRATION IN 6-OHDA LESIONED RATS

      Behavioural brain research
    57. WIKBERG T; OTTOILA P; TASKINEN J
      IDENTIFICATION OF MAJOR URINARY METABOLITES OF THE CATECHOL-O-METHYLTRANSFERASE INHIBITOR ENTACAPONE IN THE DOG

      European journal of drug metabolism and pharmacokinetics
    58. MYLLYLA VV; SOTANIEMI KA; ILLI A; SUOMINEN K; KERANEN T
      EFFECT OF ENTACAPONE, A COMT INHIBITOR, ON THE PHARMACOKINETICS OF LEVODOPA AND ON CARDIOVASCULAR-RESPONSES IN PATIENTS WITH PARKINSONS-DISEASE

      European Journal of Clinical Pharmacology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/10/20 alle ore 10:04:01